Terms: = Colorectal cancer AND XPC, XP3, 7508, ENSG00000154767, XPCC AND Treatment
3 results:
1. Validation of Genetic Markers Associated with Survival in colorectal cancer Patients Treated with Oxaliplatin-Based Chemotherapy.
Park HA; Seibold P; Edelmann D; Benner A; Canzian F; Alwers E; Jansen L; Schneider M; Hoffmeister M; Brenner H; Chang-Claude J
Cancer Epidemiol Biomarkers Prev; 2022 Feb; 31(2):352-361. PubMed ID: 34862210
[TBL] [Abstract] [Full Text] [Related]
2. Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab treatment in a Disseminated i.p. Tumor Model.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
PLoS One; 2016; 11(7):e0159904. PubMed ID: 27467592
[TBL] [Abstract] [Full Text] [Related]
3. Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer.
Kap EJ; Seibold P; Richter S; Scherer D; Habermann N; Balavarca Y; Jansen L; Becker N; Pfütze K; Popanda O; Hoffmeister M; Ulrich A; Benner A; Ulrich CM; Burwinkel B; Brenner H; Chang-Claude J
Pharmacogenomics J; 2015 Dec; 15(6):505-12. PubMed ID: 25778469
[TBL] [Abstract] [Full Text] [Related]
